GlaxoSmithKline's effort to relaunch cancer R&D faces skepticism

GlaxoSmithKline ($GSK) made a high-profile decision to exit the cancer drug field in its recent deal with Novartis ($NVS), but as Reuters reports, a band of specialists inside GSK still has ambitious plans for developing next-gen therapies. GSK is concentrating its hopes on bispecific antibodies and immuno-oncology, which has emerged as the hottest field in drug R&D. Still, the pharma giant is likely to run into considerable skepticism. "It's hard to envision GSK spending a lot of money in an area in which they no longer have a commercial presence," Marshall Gordon, healthcare analyst for ClearBridge Investments, tells Reuters. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.